Cancer Research Donn Young  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 38, 313-324, February 1, 1978]
© 1978 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gelder, F. B.
Right arrow Articles by Hunter, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gelder, F. B.
Right arrow Articles by Hunter, R.

Purification, Partial Characterization, and Clinical Evaluation of a Pancreatic Oncofetal Antigen1

F. B. Gelder2, C. J. Reese, A. R. Moossa, T. Hall and R. Hunter3

Departments of Pathology [F. B. G., C. J. R., R. H.] and Surgery [A. R. M., T. H.], The University of Chicago, and Franklin McLean Memorial Research Institute,,4 Chicago, Illinois 60637

This paper describes the purification and partial characterization of a putative pancreatic oncofetal antigen. Pancreatic oncofetal antigen is a glycoprotein with a molecular weight between 800,000 and 900,000, which migrates in the {alpha}2- to ß-region on electrophoresis. It is found in fetal pancreas and pancreatic cancer tissue, but it is not found in normal adult pancreas. Highly purified material migrated as a single band on polyacrylamide gel electrophoresis and immunized rabbits to produce monospecific antibody without absorption. Pancreatic oncofetal antigen is clearly different from carcinoembryonic antigen, other known tumor-associated antigens, acutephase reactants, and normal serum proteins. In addition, a quantitative rocket immunoelectrophoresis assay sensitive enough to detect pancreatic oncofetal antigen in the serum of most patients was developed and used to monitor the purification of pancreatic oncofetal antigen and to evaluate its clinical application.

Assays for pancreatic oncofetal antigen were carried out on three panels of sera; one was collected at The University of Chicago, and two were supplied by the Mayo-National Cancer Institute Serum Plasma Bank. The results demonstrate that pancreatic oncofetal antigen is found in the sera of most individuals; however, by far the highest absolute levels and the highest frequency of elevated levels were found in sera of patients with carcinoma of the pancreas. Elevated levels of pancreatic concofetal antigen were also observed in the serum of some patients with carcinoma of the lung, stomach, colon, biliary tract, and breast as well as in the serum of some pregnant women and other individuals with certain benign conditions. The spectrum of patients who have elevated levels of pancreatic oncofetal antigen in their serum is quite different from that found with carcinoembryonic antigen or other known tumor markers. Serial assays were performed on the sera of several patients with cancer of the pancreas; the results suggest that measurement of pancreatic oncofetal antigen may be valuable in monitoring the course of cancer of the pancreas.

1 Supported in part by USPHS Grants CA 17525 and CA 14599 and by Contract NO1-CB-43976.

2 Supported by a postdoctoral fellowship from USPHS Training Grant A1 452. To whom requests for reprints should be addressed, at Department of Pathology, The University of Chicago, Box 414, 950 East 59th Street, Chicago, Ill. 60637.

3 Recipient of USPHS Research Career Development Award CA 00032.

4 Operated by The University of Chicago for the U. S. Energy Research and Development Administration under Contract EY-76-C-02-0069.

Received 11/ 8/76. Accepted 11/ 8/77.




This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
D. K. Pleskow, H. J. Berger, J. Gyves, E. Allen, A. McLean, and D. K. Podolsky
Evaluation of a Serologic Marker, CA19-9, in the Diagnosis of Pancreatic Cancer
Ann Intern Med, May 1, 1989; 110(9): 704 - 709.
[Abstract] [PDF]


Home page
Arch SurgHome page
C. R. Mackie, J. Bowie, M. J. Cooper, M. H. Lewis, and A. R. Moossa
Ultrasonography and Tumor-associated Antigens: The Concept of Combining Noninvasive Tests in the Screening for Pancreatic Cancer
Arch Surg, August 1, 1979; 114(8): 889 - 892.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
ONCOLOGY COMMITTEE, MEDICAL KNOWLEDGE SELF-ASSESSM
Oncology: An Annotated Bibliography of Recent Literature: References to Journal Articles and Other Papers
Ann Intern Med, June 1, 1979; 90(6): 996 - 1000.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1978 by the American Association for Cancer Research.